You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In the hunt for an antigen in solid tumors that CAR T cells can target, researchers demonstrate the safety and efficacy profile of two such agents in early studies.
Data being presented at the upcoming AACR meeting show that Guardant's liquid biopsy test provided more accurate and rapid mutation detection than tissue genotyping.
CEO Brad Gray told investors at the JP Morgan Healthcare Conference that he believes the firm's GeoMx has advantages over competitors in the new market.
José Baselga, the former chief medical officer of Memorial Sloan Kettering Cancer Center, has now resigned as editor-in-chief of a cancer journal, the New York Times and ProPublica report.
The company is expecting that existing users from its technology access program are likely to purchase instruments when they become available later this year.
The company is eyeing a launch for its IVD kits at the beginning of next year, as evidence grows for the integration of TMB analysis into the clinical care of cancer patients.
Investigators and commercial firms presenting at the recent AACR meeting highlighted how heterogeneous both the technology and the application of liquid biopsy remains.
The company presented three posters at AACR, two of which demonstrated insights from its circulating DNA monitoring in colorectal and bladder cancers.
At the AACR annual meeting, researchers highlighted genomics- and proteomics-informed research aimed at establishing more effective, targeted immunotherapies.
The American Association for Cancer Research annual meeting wrapped up today in Chicago. Below are selected business briefs from the conference.